PET/CT Limitations and Pitfalls in Urogenital Cancers

Vasireddi, Anil; Nguyen, Nghi

doi:10.1053/j.semnuclmed.2021.06.013

Cited by 8 publications

(2 citation statements)

References 81 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The attractiveness of PET is attributed to its ability to identify genomic aberrations and the dysregulation of proteins [ 46 ], which cannot be detected by the previously described imaging modalities. Unfortunately, the evaluation of BCa with PET is difficult due to the accumulation of 18 F-FDG within the bladder from renal excretion, which obstructs the delineation of the tumor from the bladder wall and hinders the detection of BCa [ 49 ] ( Table 1 ).…”

Section: Non-invasive Imaging Modalitiesmentioning

confidence: 99%

Non-Invasive Imaging Modalities in Intravesical Murine Models of Bladder Cancer

Relouw

Dugbartey

Şener

2023

Cancers

View full text Add to dashboard Cite

Bladder cancer (BCa) is the sixth most prevalent cancer in men and seventeenth most prevalent cancer in women worldwide. Current treatment paradigms have limited therapeutic impact, suggesting an urgent need for the investigation of novel therapies. To best emulate the progression of human BCa, a pre-clinical intravesical murine model is required in conjunction with existing non-invasive imaging modalities to detect and evaluate cancer progression. Non-invasive imaging modalities reduce the number of required experimental models while allowing for longitudinal studies of novel therapies to investigate long-term efficacy. In this review, we discuss the individual and multi-modal use of non-invasive imaging modalities; bioluminescence imaging (BLI), micro-ultrasound imaging (MUI), magnetic resonance imaging (MRI), and positron emission tomography (PET) in BCa evaluation. We also provide an update on the potential and the future directions of imaging modalities in relation to intravesical murine models of BCa.

show abstract

Section: Non-invasive Imaging Modalitiesmentioning

confidence: 99%

Non-Invasive Imaging Modalities in Intravesical Murine Models of Bladder Cancer

Relouw

Dugbartey

Şener

2023

Cancers

View full text Add to dashboard Cite

show abstract

“…In penile cancer, FDG PET/CT is used for primary staging and for detection of recurrence [1][2][3][4]. Several pitfalls exist when reporting FDG PET/CT scans, including in urogenital malignancies5 and in infectious diseases 6,7. Only few case reports exist on FDG PET/CT in patients with syphilis [8][9][10].…”

mentioning

confidence: 99%

FDG PET/CT in a Patient With Syphilis Suspected of Having Penile Cancer

Jakobsen

Szumniak²,

Stilling³

et al. 2022

Clin Nucl Med

View full text Add to dashboard Cite

A 58-year-old man with large penile wound and enlarged regional lymph node was suspected of having disseminated penile cancer. FDG PET/ CT for primary staging showed high FDG uptake on penis and in several enlarged lymph nodes. However, biopsies revealed no signs of malignancy, but ulceration, inflammation, fibrosis, and spirochetes. Furthermore, Wassermann test was positive. The patient was then treated for syphilis. To our knowledge, this is the first report on FDG PET/CT in a patient suspected of having penile cancer that turned out to be syphilis. Thus, syphilis can be added to the list of benign pitfalls in FDG PET/CT.

show abstract